The serum concentration of Methotrexate can be increased when it is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with PTC299. Naproxen may decrease the excretion rate of Arbekacin which could result in a higher serum level. Naproxen may decrease the antihypertensive activities of Bupranolol. The risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen. The risk or severity of adverse effects can be increased when Naproxen is combined with Choline magnesium trisalicylate. The risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine. Naproxen may increase the anticoagulant activities of Dabigatran etexilate. The risk or severity of adverse effects can be increased when Naproxen is combined with Pregnenolone. The risk or severity of adverse effects can be increased when Captopril is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with 16-Bromoepiandrosterone. The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin. The metabolism of Naproxen can be decreased when combined with Sildenafil. Naproxen may increase the anticoagulant activities of Darexaban. The risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban. Naproxen may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Naproxen may decrease the antihypertensive activities of Esmolol. The risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal. The risk or severity of adverse effects can be increased when Etodolac is combined with Naproxen. Naproxen may decrease the diuretic activities of Furosemide. Naproxen may increase the anticoagulant activities of Dicoumarol. Naproxen may decrease the excretion rate of Kanamycin which could result in a higher serum level. The metabolism of Naproxen can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naproxen. Naproxen may increase the neuroexcitatory activities of Prulifloxacin. Naproxen may increase the anticoagulant activities of Acenocoumarol. Naproxen may decrease the antihypertensive activities of Pindolol. The risk or severity of adverse effects can be increased when Candoxatril is combined with Naproxen. The metabolism of Naproxen can be decreased when combined with Etravirine. The metabolism of Naproxen can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Naproxen is combined with Icatibant. The metabolism of Naproxen can be decreased when combined with Mexiletine. Naproxen may decrease the excretion rate of Idarubicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Naproxen is combined with Loxoprofen. Naproxen may decrease the antihypertensive activities of Acebutolol. Naproxen may decrease the excretion rate of Metrizamide which could result in a higher serum level. Naproxen may decrease the excretion rate of Plazomicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Naproxen is combined with Beclomethasone dipropionate. The risk or severity of adverse effects can be increased when Naproxen is combined with Parecoxib. The risk or severity of adverse effects can be increased when Naproxen is combined with Corticosterone. The risk or severity of adverse effects can be increased when Naproxen is combined with Halcinonide. Naproxen may increase the neuroexcitatory activities of Levofloxacin. The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Deflazacort. The risk or severity of adverse effects can be increased when Naproxen is combined with Prednicarbate. The risk or severity of adverse effects can be increased when Naproxen is combined with Lumiracoxib. Naproxen may decrease the antihypertensive activities of Triamterene. The risk or severity of adverse effects can be increased when Benazepril is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Desoxycorticosterone Pivalate. The risk or severity of adverse effects can be increased when Naproxen is combined with Etofenamate. The metabolism of Naproxen can be decreased when combined with Quinine. The risk or severity of adverse effects can be increased when Forasartan is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid. The metabolism of Naproxen can be decreased when combined with Ketoconazole. Naproxen may increase the anticoagulant activities of Certoparin. The risk or severity of adverse effects can be increased when Naproxen is combined with Zomepirac. The risk or severity of adverse effects can be increased when Naproxen is combined with Dexamethasone. Naproxen may increase the anticoagulant activities of Ferulic acid. The risk or severity of adverse effects can be increased when Naproxen is combined with Pirfenidone. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen. The metabolism of Naproxen can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Naproxen is combined with Felbinac. The risk or severity of adverse effects can be increased when Naproxen is combined with Evening primrose oil. Naproxen may increase the nephrotoxic activities of Cyclosporine. The metabolism of Naproxen can be decreased when combined with Tolbutamide. The risk or severity of adverse effects can be increased when Enalaprilat is combined with Naproxen. The metabolism of Naproxen can be decreased when combined with Azithromycin. Naproxen may decrease the excretion rate of Neamine which could result in a higher serum level. Naproxen may decrease the excretion rate of Apramycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Naproxen is combined with Medrysone. The risk or severity of adverse effects can be increased when Naproxen is combined with Indoprofen. Naproxen may decrease the antihypertensive activities of Metoprolol. The risk or severity of adverse effects can be increased when Etanercept is combined with Naproxen. The metabolism of Naproxen can be decreased when combined with Gemfibrozil. The therapeutic efficacy of Latanoprost can be decreased when used in combination with Naproxen. The metabolism of Naproxen can be decreased when combined with Sulfadiazine. The risk or severity of adverse effects can be increased when Bromfenac is combined with Naproxen. The serum concentration of Naproxen can be decreased when it is combined with Osimertinib. The metabolism of Naproxen can be increased when combined with Carbamazepine. Naproxen may decrease the antihypertensive activities of Aliskiren. The serum concentration of Vancomycin can be increased when it is combined with Naproxen. The metabolism of Naproxen can be decreased when combined with Losartan. The risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasol propionate. The metabolism of Naproxen can be decreased when combined with Zucapsaicin. Naproxen may decrease the antihypertensive activities of Timolol. The risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen. The therapeutic efficacy of Quinethazone can be decreased when used in combination with Naproxen. The therapeutic efficacy of Limaprost can be decreased when used in combination with Naproxen. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Naproxen. Naproxen may decrease the antihypertensive activities of Oxprenolol. The metabolism of Naproxen can be decreased when combined with Celecoxib. Naproxen may increase the anticoagulant activities of Phenindione. The risk or severity of adverse effects can be increased when Naproxen is combined with anecortave acetate. The risk or severity of adverse effects can be increased when Naproxen is combined with Nitroaspirin. The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naproxen. The metabolism of Naproxen can be decreased when combined with Voriconazole. Naproxen may decrease the antihypertensive activities of Bucindolol. The risk or severity of adverse effects can be increased when Naproxen is combined with Amcinonide. The risk or severity of adverse effects can be increased when Naproxen is combined with Formestane. The serum concentration of Naproxen can be increased when it is combined with Vemurafenib. The serum concentration of Lithium can be increased when it is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Flunisolide. The metabolism of Naproxen can be decreased when combined with Topiroxostat. The therapeutic efficacy of Folic Acid can be decreased when used in combination with Naproxen. The risk or severity of adverse effects can be increased when Olopatadine is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Loteprednol. Naproxen may decrease the antihypertensive activities of Celiprolol. The risk or severity of bleeding can be increased when Betrixaban is combined with Naproxen. Naproxen may increase the anticoagulant activities of Nafamostat. The risk or severity of adverse effects can be increased when Naproxen is combined with Triamcinolone. Naproxen may increase the hyperkalemic activities of Drospirenone. The risk or severity of adverse effects can be increased when Omapatrilat is combined with Naproxen. The metabolism of Naproxen can be decreased when combined with Sulfisoxazole. Naproxen may decrease the excretion rate of Epirubicin which could result in a higher serum level. Naproxen may increase the anticoagulant activities of Letaxaban. The risk or severity of adverse effects can be increased when Naproxen is combined with Droxicam. The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naproxen. The metabolism of Naproxen can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Naproxen is combined with Triptolide. Naproxen may increase the anticoagulant activities of Pentosan Polysulfate. The risk or severity of adverse effects can be increased when Enalapril is combined with Naproxen. The risk or severity of adverse effects can be increased when Floctafenine is combined with Naproxen. Naproxen may increase the neuroexcitatory activities of Pefloxacin. The risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid. The risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol. The risk or severity of adverse effects can be increased when Treprostinil is combined with Naproxen. The risk or severity of adverse effects can be increased when Naproxen is combined with Fluprednidene. Naproxen may decrease the excretion rate of Valrubicin which could result in a higher serum level. Naproxen may decrease the excretion rate of Gentamicin which could result in a higher serum level. Naproxen may decrease the antihypertensive activities of Platelet Activating Factor.